Acute Vulvovaginal Candidiasis Treatment Market
According to Intent Market Research, the Acute Vulvovaginal Candidiasis Treatment Market is expected to grow from USD 1.3 billion in 2023 at a CAGR of 7.7% to touch USD 2.1 billion by 2030. The Acute Vulvovaginal Candidiasis Treatment Market is dominated by key players such as, Johnson & Johnson, Pfizer Inc., Bayer AG, Mylan N.V., and Teva Pharmaceutical Industries Ltd